Evidence map›Paper›PMID 35003749›Full record

ArticleClinical & translational immunology2022

Maintained partial protection against

Giuseppe Ercoli, Elisa Ramos-Sevillano, Emma Pearce, Sara Ragab, David Goldblatt, Gisbert Weckbecker, Jeremy S Brown

Open access · goldAbstract read
In one paragraph

Article in Clinical & translational immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Giuseppe ErcoliCentre for Inflammation and Tissue Repair UCL Respiratory Division of Medicine University College Medical School Rayne Institute London UK.ORCID https://orcid.org/0000-0001-7326-1680
Elisa Ramos-SevillanoCentre for Inflammation and Tissue Repair UCL Respiratory Division of Medicine University College Medical School Rayne Institute London UK.
Emma PearceDepartment of Immunobiology UCL Great Ormond Street Institute of Child Health NIHR Biomedical Research Centre London UK.
Sara RagabDepartment of Immunobiology UCL Great Ormond Street Institute of Child Health NIHR Biomedical Research Centre London UK.
David GoldblattDepartment of Immunobiology UCL Great Ormond Street Institute of Child Health NIHR Biomedical Research Centre London UK.
Gisbert WeckbeckerNovartis Institute for BioMedical Research Novartis Basel Switzerland.
Jeremy S BrownCentre for Inflammation and Tissue Repair UCL Respiratory Division of Medicine University College Medical School Rayne Institute London UK.
Centre for Inflammation Research · GBUCL Biomedical Research Centre · GBNovartis (Switzerland) · CH

Funding

Medical Research Council MR/N02687X/1Medical Research Council MR/R001871/1
6 · The paper itself

Abstract

objectivesAnti-CD20 monoclonal antibody therapy rapidly depletes > 95% of CD20

methodsC57BL/6 female mice were B-cell depleted using anti-CD20 antibody and immunized with two doses of Prevnar-13 vaccine either before or after anti-CD20 treatment. B-cell repertoire and

resultsAntibody responses to

conclusionsThis study showed that although vaccine efficacy during periods of profound B-cell depletion was impaired some protective efficacy was preserved, suggesting that vaccination remains beneficial.

Indexed as

B‐cell depletionCD20immunityStreptococcus pneumoniaevaccination

Identifiers

PMID35003749
PMCPMC8715227
OpenAlexW4200138858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.